{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Clearside Biomedical, Inc."},"Symbol":{"label":"Symbol","value":"CLSD"},"Address":{"label":"Address","value":"900 NORTH POINT PARKWAY,SUITE 200, ALPHARETTA, Georgia, 30005, United States"},"Phone":{"label":"Phone","value":"+1 678 270-3631"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision."},"CompanyUrl":{"label":"Company Url","value":"https://www.clearsidebio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"George M. Lasezkay","title":"President, Chief Executive Officer & Director"},{"name":"Rafael V. Andino","title":"Senior VP-Engineering & Manufacturing"},{"name":"Susan L. Coultas","title":"Chief Clinical Officer"},{"name":"Victor Chong","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}